



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

December 6, 2022: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**

- **Chief Medical Officer Updates** **6:45 - 6:50**

- **Follow-up Items from Previous Meetings** **6:50 – 7:00**
 - Substance Use Disorder Treatments

- **RetroDUR/ProDUR** **7:00- 7:25**
 - Data presentation: Metabolic Monitoring for Children and Adolescents on Antipsychotics
 - Introduce: 1st RetroDUR initiative for 2023

- **Clinical Update: Drug Reviews** **7:25-7:55**
(Public comment prior to Board action)
 - **Biosimilar Drug Reviews**
 - None at this time.

 - **Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Adlarity® (donepezil transdermal system)
 - Epsolay® (benzoyl peroxide)
 - Ibsrela® (tenapanor)
 - Quviviq® (daridorexant)
 - Tlando® (testosterone undecanoate)
 - Twyneo® (tretinoin & benzoyl peroxide)
 - Vyvgart ® (efgartigimod alfa-fcab)

- **New Managed Therapeutic Drug Classes** **7:55 -7:55**
 - None at this time

(Public comment prior to Board action)

- None at this time

▪ **Therapeutic Drug Classes – Periodic Review** **7:55 - 8:20**

(Public comment prior to Board action)

- Antihistamines, minimally sedating
- Alzheimer's Agents (new drug Adlarity® (donepezil transdermal system) included)
- IBS (new drug Ibsrela®(tenapanor) included)
- Intranasal Rhinitis
- Leukotriene Modifiers
- Parathyroid Agents
- Sedative Hypnotics (new drug Quviviq® (daridorexant) included)
- Smoking Cessation

▪ **Review of Newly Developed/Revised Criteria** **8:20 - 8:25**

(Public comment prior to Board action)

- Injectable Testosterone

▪ **General Announcements** **8:25 – 8:30**

Selected FDA Safety Alerts

FDA Announces Preliminary Assessment that Certain Naloxone Products Have the Potential to be Safe and Effective for Over-the-Counter Use

<https://www.fda.gov/news-events/press-announcements/fda-announces-preliminary-assessment-certain-naloxone-products-have-potential-be-safe-and-effective>

▪ **Adjourn**
8:30